Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan, Pembrolizumab and SBRT in Recurrent, Refractory, or Oligometastatic HNSCC
NCT06211335Phase 1Recruiting
- Sponsor
- University of California, Davis
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of losartan in head and neck squamous cell carcinoma (HNSCC), sponsored by University of California, Davis. Primary endpoint: Incidence of treatment related adverse events at 2 years. Started Dec 2023; status: recruiting.
02
Drugs
losartan
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06211335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211335.